# US 2020/0395097 A1 · Pan-cancer model to predict the pd-l1 status of a cancer cell sample using rna expression data and other patient data

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0395097 A1
- Document ID: US20200395097A1
- Status: Published application
- Kind: A1
- Application number: 16/888,357
- Filed: 2020-05-29
- Published: 2020-12-17
- Earliest claimed: 2019-05-30
- Assignees: Tempus Labs, Inc.
- Applicants: Tempus Labs, Inc.
- Inventors: Alan Chang; Denise Lau; Aly Azeem Khan
- Web page: https://patentgrep.com/patent/US20200395097A1

## CPC

- G16B 30/10: Sequence alignment; Homology search
- G16B 5/20: Probabilistic models
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16B 40/20: Supervised data analysis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Provided herein are computer-implemented methods of identifying programmed-death ligand 1 (PD-L1) expression status of a subject's sample comprising a cancer cell. In exemplary embodiments, the method comprises receiving an unlabeled expression data set for the subject's sample; aligning the unlabeled expression data set to labeled expression data according to a trained PD-L1 predictive model, wherein the trained PD-L1 predictive model has been trained with a plurality of labeled expression data sets, each labeled expression data set comprising expression data for a sample of a labeled cancer type and a labeled PD-L1 expression status; wherein aligning the unlabeled gene expression data set to labeled expression data according to the trained PD-L1 predictive model identifies PD-L1 expression status for the subject's sample. Further provided are related methods of preparing a clinical decision support information (CDSI) report and methods of determining treatment for a subject. Additionally provided are CDSI reports and computing devices.

## Claims

### Claim 1

A computer-implemented method of identifying programmed-death ligand 1 (PD-L1) expression status of a subject's sample comprising a cancer cell, the method comprising:
receiving an unlabeled expression data set for the subject's sample; and
aligning the unlabeled expression data set to labeled expression data according to a trained PD-L1 predictive model, wherein the trained PD-L1 predictive model has been trained with a plurality of labeled expression data sets, each labeled expression data set comprising expression data for a sample of a labeled PD-L1 expression status;
wherein aligning the unlabeled gene expression data set to labeled expression data according to the trained PD-L1 predictive model identifies PD-L1 expression status for the subject's sample.

### Claim 2 (depends on 1)

The computer-implemented method of claim 1, wherein the trained PD-L1 predictive model has been trained by (i) inputting a plurality of labeled expression data sets, wherein each labeled expression data set comprises a labeled cancer type and a labeled PD-L1 expression status, and, optionally, one or more labeled features.

### Claim 3 (depends on 2)

The computer-implemented method of claim 2, wherein the plurality of labeled expression data sets comprises expression data for samples of a single cancer type.

### Claim 4 (depends on 2)

The computer-implemented method of claim 2, wherein the plurality of labeled expression data sets comprises expression data for samples of 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different cancer types.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 2)

The computer-implemented method of claim 2, wherein the plurality of labeled expression data sets comprises expression data for breast cancer, prostate cancer, colorectal cancer, lung cancer, skin cancer, kidney cancer, pancreatic cancer, stomach cancer, or a combination thereof.

### Claim 8 (depends on 2)

The computer-implemented method of claim 2, wherein the plurality of labeled expression data sets comprises expression data for a subtype of one or more of labeled cancer type(s), optionally, a subtype of breast cancer.

### Claim 9 (depends on 8)

The computer-implemented method of claim 8, wherein the subtype for breast cancer is luminal breast cancer, triple negative breast, or a combination thereof.

### Claim 10 (depends on 2)

The computer-implemented method of claim 2, wherein the plurality of labeled expression data sets comprises expression data for lung adenocarcinoma, melanoma, renal cell carcinoma, bladder cancer, mesothelioma, and lung small cell cancer.

### Claim 11 (depends on 2)

The computer-implemented method of claim 2, wherein the labeled expression data comprises RNA expression data, optionally, mRNA expression data.

### Claim 12 (depends on 11)

The computer-implemented method of claim 11, wherein the mRNA expression data is RNA-seq data.

### Claim 13 (depends on 12)

The computer-implemented method of claim 12, wherein the RNA-seq data is normalized RNA-seq data.

### Claim 14 (depends on 1)

The computer-implemented method of claim 1, wherein the unlabeled expression data set for the sample comprises RNA expression data, optionally, mRNA expression data.

### Claim 15 (depends on 14)

The computer-implemented method of claim 14, wherein the mRNA expression data is RNA-seq data.

### Claim 16 (depends on 15)

The computer-implemented method of claim 15, wherein the RNA seq data is normalized RNA-seq data.

### Claim 17 (depends on 1)

The computer-implemented method of claim 1, further comprising one or more of: obtaining the sample from a subject, isolating mRNA from cells of the sample, fragmenting the mRNA, producing double-stranded cDNA based on the mRNA fragments, carrying out high throughput, short-read sequencing on the cDNA, aligning the sequences to a reference genome, and normalizing raw RNA-seq data.

### Claim 18 (depends on 17)

The computer-implemented method of claim 17, wherein the high throughput, short-read sequencing is next generation sequencing (NGS), optionally, wherein the NGS comprises hybrid capture.

### Claim 19 (depends on 18)

The computer-implemented method of claim 18, wherein the hybrid capture comprises use of biotinylated probes which bind to specific target nucleotide sequences.

### Claim 20 (depends on 19)

The computer-implemented method of claim 19, wherein at least one of the target nucleotide sequences encodes PD-L1, PD-1, or a combination thereof.

### Claim 21 (depends on 19)

The computer-implemented method of claim 19, wherein at least one of the target nucleotide sequences encodes 4-1BB, TIM-3, or other immune checkpoint blockade molecules.

### Claim 22 (depends on 2)

The computer-implemented method of claim 2, wherein each labeled expression data set further comprises data from images, image features, clinical data, epigenetic data, pharmacogenetic data, metabolomics data, or a combination thereof.

### Claim 23 (depends on 1)

The computer-implemented method of claim 1, wherein the unlabeled expression data set further comprises data from images, image features, clinical data, epigenetic data, pharmacogenetic data, metabolomics data, or a combination thereof, of the subject.

### Claim 24 (depends on 1)

The computer-implemented method of claim 1, wherein the trained PD-L1 predictive model has been trained with a plurality of labeled expression data sets, each labeled expression data set comprises one or more labeled features, and the trained PD-L1 predictive model has been trained according to select labeled features pre-determined to have an association with a phenotype of biological relevance.

### Claim 25 (depends on 24)

The computer-implemented method of claim 24, wherein the trained PD-L1 predictive model was trained using a clustering algorithm to determine which labeled features associate with the phenotype of biological relevance.

### Claim 26 (depends on 25)

The computer-implemented method of claim 25, wherein the phenotype of biological relevance is PD-L1 expression status.

### Claim 27 (depends on 24)

The computer-implemented method of claim 24, wherein the at least one or more of the select labeled features comprises expression data for at least one gene selected from the group consisting of CD274, TIGIT, CXCL13, IL21, FASLG, TFPI2, GAGE12C, POMC, PAX6, NPHS1, HLA-DPB1, PDCD1, PDCD1LG2, IFNG, GZMB, CXCL9, TGFB1, VIM, STX2, and ZEB2.

### Claim 28 (depends on 1)

The computer-implemented method of claim 1, wherein the trained PD-L1 predictive model is a logistic regression model, a random forest model, or a support vector machine (SVM) model, optionally, wherein the logistic regression model is a single-gene or multi-gene logistic regression model.

### Claim 29 (depends on 1)

The computer-implemented method of claim 1, wherein the labeled PD-L1 expression status is based on an reverse phase protein array (RPPA) data, fluorescence in situ hybridization (FISH) data, immunohistochemistry (IHC) data, or a combination thereof, optionally, wherein the trained PD-L1 predictive model correlates the labeled PD-L1 expression status with select labeled expression data and/or labeled features.

### Claim 30 (depends on 1)

The computer-implemented method of claim 1, the method further comprising:
generating a clinical decision support information (CDSI) report including at least the subject's identity and the identified PD-L1 expression status, and, optionally, providing the CDSI report to a healthcare provider for use in selecting a candidate therapy based on the identified PD-L1 expression status for the subject's sample.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)
